Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 48-Month Extension to the Randomized, Double-blind, Placebo-Controlled Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer

NCT00732043 is registered in ClinicalTrials.gov with Roll International Corporation as lead sponsor.

NCT NCT00732043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00732043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 48-Month Extension to the Randomized, Double-blind, Placebo-Controlled Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer
Lead sponsor
Roll International Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2007
Completion date
January 31, 2015
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer